Practical workshops

Watch patient–doctor consultations to understand how patient fears can be managed and how to best tailor treatment to the individual

Both videos will incorporate comments and insights from Professor Simon Heller and Dr Emma Wilmot.

Each workshop will take up to 30 minutes to complete. To claim your CME credits, select the box in the evaluation form at the end of the activity.

"We discuss how my patient can better achieve recommended glucose targets and reduce her risk of hypoglycemia despite a variable lifestyle" – Workshop 1

"A woman with severe problematic hypoglycemia, which affects approximately 1 in 10 adults with type 1 diabetes, arrives at the surgery with her husband, who expresses his concern about her hypoglycemia unawareness". – Workshop 2

Professor Stephanie Amiel
Professor Stephanie Amiel
CME accreditation is available

Continuing Medical Education

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.

NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

NACCME designates AMA PRA Category Credit(s)™ for the following activities:

Completion of each workshop: AMA PRA Category 0.5 Credits™

How To Claim Your Credits

To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.

During completion of the evaluation form, you can select the box that indicates accreditation is required. Learners will receive their CME certificate, via email, within 1 month of placing their request in the evaluation form of the respective module. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Disclosure of Relevant Financial Relationships

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

NACCME requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Planning Committee

In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include Chris Bolwell, Jennifer Ilcyn, Jules Morgan, and Rebecca Cox.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

Jennifer Ilcyn, Jules Morgan, and Rebecca Cox have no financial relationships to disclose.

Emma Wilmot

Emma Wilmot is Consultant Diabetologist, University Hospitals of Derby and Burton NHS Foundation Trust and Honorary (consultant) Assistant Professor, University of Nottingham.

Dr Wilmot’s specialist interests include Type 1 diabetes, insulin pump therapy and diabetes technology, young adults with diabetes and antenatal diabetes care.

Dr Wilmot is chair of the ABCD Diabetes Technology Network UK. In this role she leads the delivery of a program of educational events for multidisciplinary diabetes teams. She has led the development of a suite of national ‘best practice’ guides related to insulin pump therapy and is a member of the National Diabetes Audit Insulin Pump Expert Reference Group, developing the 2018 national Type 1 diabetes service level audit. Dr Wilmot has been involved in the #language matters movement which aims to improve healthcare professional communication with people with diabetes.

Dr Wilmot was awarded the University of Leicester medal for excellent PhD performance in 2013 for her PhD “Type 2 diabetes in younger adults”.

Disclosures

Personal fees from Abbott Diabetes Care, Dexcom, Diasend, Eli Lilly, Medtronic, Novo Nordisk, Sanofi Aventis.

Stephanie Amiel

Stephanie Amiel is professor of diabetes research at Kings College, London, UK. She is an experimental medicine researcher with interests in the prevention and management of hypoglycemia in diabetes treatments and the role of the brain in control of metabolism. She also conducts research in the impact of ethnicity on metabolism. Professor Amiel trained at Guy’s Hospital with Professor Harry Keen and started her research career at Yale, with Professors Robert Sherwin and William Tamborlane. She led the King’s team in a collaboration with Sheffield and North Tyneside in the creation of DAFNE, the UK’s first national structured education program in flexible insulin therapy for adults with type 1 diabetes and continues to research in the area. With colleagues in the King’s Liver Unit, she set up the King’s human islet isolation and transplantation service and has developed services at King’s College Hospital NHS Foundation Trust for supporting adults with Type 1 diabetes and pregnancy in diabetes.

Her current research includes neuroimaging to investigate the role of the brain in hypoglycemia defenses in type 1 diabetes and in appetite control in insulin resistance and she is currently running the HARPdoc randomized controlled trial of a novel intervention for treatment-resistant hypoglycemia in adults with type 1 diabetes, looking at the impact of cognitions on hypoglycemia avoidance behaviors. Professor Amiel was awarded the Banting Memorial Lecture of Diabetes UK, the highest award bestowed by the charity, in 2013. She chaired the Guideline Development Group for the diagnosis and management of type 1 diabetes in adults, published in 2015, and currently chairs the Strategic Research Advisory Group for Diabetes UK and is a mentor on the EFSD Mentorship program.

Disclosures

Received grants/research support or honoraria/consultation fees from Novo Nordisk, Medronic and Roche.

Simon Heller

Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, and Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust.

He trained in clinical diabetes at Queen’s Medical Centre, Nottingham and in research at the University of Nottingham and Washington University, St Louis, USA.  He was Editor of Diabetic Medicine from 2000-2005.  He is currently the National Speciality Lead in Diabetes to the NIHR Clinical Research Network and an NIHR Senior Investigator. He is a former member of Diabetes UK Science and Research Advisory Group, a member of the UK NIHR Programme Grants for Applied Research Panel and chairs the UK Juvenile Diabetes Research Foundation, UK Scientific Advisory Committee. 

He chairs the International Hypoglycaemia Study group, an independently funded group of international experts with research and clinical expertise in hypoglycaemia.  The group has a remit to reduce the burden of hypoglycemia though educational activities.

He chaired the glucose control group of the ADVANCE trial, is a steering committee member of the EXAMINE trial and was the PI on the REPOSE trial measuring the effectiveness of insulin pumps.

His research interests include the pathophysiological responses to hypoglycemia and hypoglycemia unawareness, the potential contribution and mechanisms of hypoglycemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycemia.  He also conducts research concerned with developing programs (including the DAFNE intervention) to encourage more effective diabetes self-management.  He has authored over 200 original research articles and reviews.

Disclosures

Advisory Board Member for Eli Lilly, Novo Nordisk, Sanofi Aventis, Takeda, Zealand Pharma, UN-EEG and Boehringer Ingelheim. Consultant for Eli Lilly and Novo Nordisk. On the Speaker’s Bureau for Eli Lilly and Novo Nordisk.

Personalizing treatment for a variable lifestyle

Upon successful completion of this activity, learners will be able to:

  1. Identify the underlying behavioral and psychological issues associated with problematic hypoglycemia.
  2. Utilize effective communication skills that can lead to improved adherence and patient self-management behaviors.

A case of severe hypoglycemia unawareness

Upon successful completion of this activity, learners will be able to:

  1. Identify the underlying behavioral, cognitive and psychological issues associated with problematic hypoglycemia.
  2. Utilize effective communication skills that can lead to improved adherence and patient self-management behaviors.

Personalizing treatment for a variable lifestyle

A case of severe hypoglycemia unawareness

Please create a free account or login to access this content

Scroll to Top

Please create a free account or login to access this content

Register

  • This field is for validation purposes and should be left unchanged.
* Required

Login

Forgot Password?

Contact us

  • This field is for validation purposes and should be left unchanged.

Sign up

* indicates required